Moreover, hepatic steatosis—a risk factor for accelerated fibrogenesis and development of hepatocellular carcinoma [10]—is recognized as the liver manifestation of MetS, and hepatic steatosis and MetS share pathophysiological mechanisms, with insulin resistance playing a pivotal role [11]. Here, INS is linked to metabolic syndrome.